BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprani D, Esposito A, Landoni L, Casetti L, Tuveri M, Paiella S, Casciani F, Sereni E, Binco A, Bonamini D, Secchettin E, Auriemma A, Merz V, Simionato F, Zecchetto C, D'Onofrio M, Melisi D, Bassi C, Salvia R. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surg 2019;154:932-42. [PMID: 31339530 DOI: 10.1001/jamasurg.2019.2277] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Hank T, Strobel O. Conversion Surgery for Advanced Pancreatic Cancer. J Clin Med 2019;8:E1945. [PMID: 31718103 DOI: 10.3390/jcm8111945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
2 Pandé R, Roberts KJ. Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer-Where Is the Least Harm and Most Benefit? Front Oncol 2019;9:1060. [PMID: 31681596 DOI: 10.3389/fonc.2019.01060] [Reference Citation Analysis]
3 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Paiella S, Malleo G, Simoni N, Micera R, Guariglia S, Cavedon C, Marchegiani G, Esposito A, Landoni L, Casetti L, Tuveri M, Milella M, Secchettin E, Manzini G, Bovo C, De Pastena M, Fontana M, Salvia R, Mazzarotto R, Bassi C. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma. BMC Cancer 2021;21:165. [PMID: 33593311 DOI: 10.1186/s12885-021-07877-7] [Reference Citation Analysis]
5 Vernuccio F, Messina C, Merz V, Cannella R, Midiri M. Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. Diagnostics (Basel) 2021;11:2166. [PMID: 34829513 DOI: 10.3390/diagnostics11112166] [Reference Citation Analysis]
6 Soer EC, Verbeke CS. Pathology reporting of margin status in locally advanced pancreatic cancer: challenges and uncertainties. J Gastrointest Oncol 2021;12:2512-20. [PMID: 34790412 DOI: 10.21037/jgo-20-391] [Reference Citation Analysis]
7 Le Grazie M, Conti Bellocchi MC, Bernardoni L, Fusaroli P, Manfrin E, Pallio S, Gabbrielli A, Crinò SF. Diagnostic yield of endoscopic ultrasound-guided tissue acquisition of solid pancreatic lesions after inconclusive percutaneous ultrasound-guided tissue acquisition. Scand J Gastroenterol 2020;55:1108-13. [PMID: 32684051 DOI: 10.1080/00365521.2020.1794021] [Reference Citation Analysis]
8 Tuveri M, Milani E, Marchegiani G, Landoni L, Torresani E, Capelli P, Scarpa A, Salvia R, Vergara C, Bassi C. Hemodynamics and remodeling of the portal confluence in patients with malignancies of the pancreatic head: a pilot study towards planned and circumferential vein resections. Langenbecks Arch Surg 2021. [PMID: 34432127 DOI: 10.1007/s00423-021-02309-3] [Reference Citation Analysis]
9 Jain A, Yip D, Gananadha S. Neoadjuvant Chemotherapy in Pancreatic Cancer. JAMA Surg 2021;156:396-7. [PMID: 33439223 DOI: 10.1001/jamasurg.2020.6276] [Reference Citation Analysis]
10 Mima K, Hayashi H, Nakagawa S, Matsumoto T, Kinoshita S, Matsumura K, Kitamura F, Uemura N, Nakao Y, Itoyama R, Kaida T, Imai K, Yamashita YI, Baba H. Frailty is associated with poor prognosis after resection for pancreatic cancer. Int J Clin Oncol 2021. [PMID: 34235599 DOI: 10.1007/s10147-021-01983-z] [Reference Citation Analysis]
11 Kawasaki H, Hoshikawa M, Kyoden Y, Iijima T, Kojima H, Yamamoto J. A locally advanced pancreatic body cancer presenting common bile duct invasion resected via distal pancreatectomy after gemcitabine plus nab-paclitaxel chemotherapy: A case report. International Journal of Surgery Case Reports 2022. [DOI: 10.1016/j.ijscr.2022.106818] [Reference Citation Analysis]
12 Marchegiani G, Andrianello S, Nessi C, Giuliani T, Malleo G, Paiella S, Salvia R, Bassi C. Seasonal variations in pancreatic surgery outcome A retrospective time-trend analysis of 2748 Whipple procedures. Updates Surg 2020;72:693-700. [PMID: 32816284 DOI: 10.1007/s13304-020-00868-6] [Reference Citation Analysis]
13 Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020;155:832-839. [PMID: 32667641 DOI: 10.1001/jamasurg.2020.2286] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 26.0] [Reference Citation Analysis]
14 Paiella S, Casetti L, Ewald J, Marchese U, D'Onofrio M, Garnier J, Landoni L, Gilabert M, Manzini G, Esposito A, Secchettin E, Malleo G, Lionetto G, De Pastena M, Bassi C, Delpero JR, Salvia R, Turrini O. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. J Surg Res 2021;259:1-7. [PMID: 33278792 DOI: 10.1016/j.jss.2020.10.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhou Y, Liao S, You J, Wu H. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature. Updates Surg 2021. [PMID: 34021484 DOI: 10.1007/s13304-021-01089-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yamada S, Fujii T, Yamamoto T, Takami H, Yoshioka I, Yamaki S, Sonohara F, Shibuya K, Motoi F, Hirano S, Murakami Y, Inoue H, Hayashi M, Hashimoto D, Murotani K, Kitayama J, Ishikawa H, Kodera Y, Sekimoto M, Satoi S. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. J Gastrointest Oncol 2021;12:S110-7. [PMID: 33968431 DOI: 10.21037/jgo-20-243] [Reference Citation Analysis]
17 Salvia R, Malleo G, Maggino L, Milella M, Bassi C. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?Updates Surg. 2020;72:321-324. [PMID: 32445032 DOI: 10.1007/s13304-020-00798-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Trestini I, Paiella S, Sandini M, Sperduti I, Elio G, Pollini T, Melisi D, Auriemma A, Soldà C, Bonaiuto C, Tregnago D, Avancini A, Secchettin E, Bonamini D, Lanza M, Pilotto S, Malleo G, Salvia R, Bovo C, Gianotti L, Bassi C, Milella M. Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma.Ann Surg Oncol. 2020;27:5325-5334. [PMID: 32388740 DOI: 10.1245/s10434-020-08515-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
19 Damm M, Efremov L, Birnbach B, Terrero G, Kleeff J, Mikolajczyk R, Rosendahl J, Michl P, Krug S. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:4326. [PMID: 34503138 DOI: 10.3390/cancers13174326] [Reference Citation Analysis]
20 Janssen QP, O'Reilly EM, van Eijck CHJ, Groot Koerkamp B. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.Front Oncol. 2020;10:41. [PMID: 32083002 DOI: 10.3389/fonc.2020.00041] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
21 Turner KM, Delman AM, Vaysburg DM, Kharofa JR, Smith MT, Choe KA, Olowokure O, Sohal D, Wilson GC, Ahmad SA, Patel SH. Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough? Ann Surg Oncol 2022. [PMID: 35141802 DOI: 10.1245/s10434-022-11363-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Ryckman JM, Reames BN, Klute KA, Hall WA, Baine MJ, Abdel-Wahab M, Lin C. The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change? Clin Transl Radiat Oncol 2021;28:124-8. [PMID: 33981865 DOI: 10.1016/j.ctro.2021.04.002] [Reference Citation Analysis]
23 Mazzarotto R, Simoni N, Guariglia S, Rossi G, Micera R, De Robertis R, Pierelli A, Zivelonghi E, Malleo G, Paiella S, Salvia R, Cavedon C, Milella M, Bassi C. Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar. Front Oncol 2020;10:600940. [PMID: 33392093 DOI: 10.3389/fonc.2020.600940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Rossi G, Simoni N, Paiella S, Rossi R, Venezia M, Micera R, Malleo G, Salvia R, Giuliani T, Di Gioia A, Auriemma A, Milella M, Guariglia S, Cavedon C, Bassi C, Mazzarotto R. Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. Front Oncol 2021;11:662205. [PMID: 33959509 DOI: 10.3389/fonc.2021.662205] [Reference Citation Analysis]
25 Tsai HJ, Chang JS. Environmental Risk Factors of Pancreatic Cancer. J Clin Med. 2019;8. [PMID: 31510046 DOI: 10.3390/jcm8091427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
26 Walma MS, Brada LJ, Patuleia SIS, Blomjous JG, Bollen TL, Bosscha K, Bruijnen RC, Busch OR, Creemers GJ, Daams F, van Dam R, Festen S, Jan de Groot D, Willem de Groot J, Mohammad NH, Hermans JJ, de Hingh IH, Kerver ED, van Leeuwen MS, van der Leij C, Liem MS, van Lienden KP, Los M, de Meijer VE, Meijerink MR, Mekenkamp LJ, Nederend J, Nio CY, Patijn GA, Polée MB, Pruijt JF, Renken NS, Rombouts SJ, Schouten TJ, Stommel MWJ, Verweij ME, de Vos-Geelen J, de Vries JJJ, Vulink A, Wessels FJ, Wilmink JW, van Santvoort HC, Besselink MG, Molenaar IQ; Dutch Pancreatic Cancer Group. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. Eur J Surg Oncol 2021;47:699-707. [PMID: 33280952 DOI: 10.1016/j.ejso.2020.11.137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Cecchini M, Miccio JA, Pahade J, Lacy J, Salem RR, Johnson SB, Blakaj A, Stein S, Kortmansky JS, Johung KL. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas 2020;49:904-11. [PMID: 32658074 DOI: 10.1097/MPA.0000000000001592] [Reference Citation Analysis]
28 Simoni N, Micera R, Paiella S, Guariglia S, Zivelonghi E, Malleo G, Rossi G, Addari L, Giuliani T, Pollini T, Cavedon C, Salvia R, Milella M, Bassi C, Mazzarotto R. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. Clin Oncol (R Coll Radiol). 2021;33:e31-e38. [PMID: 32682686 DOI: 10.1016/j.clon.2020.06.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
29 Kato H, Horiguchi A, Ito M, Asano Y, Arakawa S. Essential updates 2019/2020: Multimodal treatment of localized pancreatic adenocarcinoma: Current topics and updates in survival outcomes and prognostic factors. Ann Gastroenterol Surg 2021;5:132-51. [PMID: 33860134 DOI: 10.1002/ags3.12427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Rossi G, Altabella L, Simoni N, Benetti G, Rossi R, Venezia M, Paiella S, Malleo G, Salvia R, Guariglia S, Bassi C, Cavedon C, Mazzarotto R. Computed tomography-based radiomic to predict resectability in locally advanced pancreatic cancer treated with chemotherapy and radiotherapy. World J Gastrointest Oncol 2022; 14(3): 703-715 [DOI: 10.4251/wjgo.v14.i3.703] [Reference Citation Analysis]
31 Perri G, Prakash L, Katz MHG. Defining and Treating Borderline Resectable Pancreatic Cancer. Curr Treat Options Oncol 2020;21:71. [PMID: 32725270 DOI: 10.1007/s11864-020-00769-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Trestini I, Cintoni M, Rinninella E, Grassi F, Paiella S, Salvia R, Bria E, Pozzo C, Alfieri S, Gasbarrini A, Tortora G, Milella M, Mele MC. Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. World J Gastrointest Surg 2021; 13(9): 885-903 [PMID: 34621468 DOI: 10.4240/wjgs.v13.i9.885] [Reference Citation Analysis]
33 Lindemann J, du Toit L, Kotze U, Bernon M, Krige J, Jonas E. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis. HPB (Oxford) 2021;23:173-86. [PMID: 33268268 DOI: 10.1016/j.hpb.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Frigerio I, Paiella S, Barbi E, Bianco R, Boz G, Butturini G, Cantore M, Cardarelli N, Mirko D, Fiorentini G, Giardino A, Lionetto G, Malleo G, Mambrini A, Milella M, Passardi A, Regi P, Salvia R, Scopelliti F, Viviani E, Bassi C, Girelli R. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Pancreatology 2021:S1424-3903(21)00481-6. [PMID: 34215498 DOI: 10.1016/j.pan.2021.06.005] [Reference Citation Analysis]
35 Walma MS, Rombouts SJ, Brada LJH, Borel Rinkes IH, Bosscha K, Bruijnen RC, Busch OR, Creemers GJ, Daams F, van Dam RM, van Delden OM, Festen S, Ghorbani P, de Groot DJ, de Groot JWB, Haj Mohammad N, van Hillegersberg R, de Hingh IH, D'Hondt M, Kerver ED, van Leeuwen MS, Liem MS, van Lienden KP, Los M, de Meijer VE, Meijerink MR, Mekenkamp LJ, Nio CY, Oulad Abdennabi I, Pando E, Patijn GA, Polée MB, Pruijt JF, Roeyen G, Ropela JA, Stommel MWJ, de Vos-Geelen J, de Vries JJ, van der Waal EM, Wessels FJ, Wilmink JW, van Santvoort HC, Besselink MG, Molenaar IQ; Dutch Pancreatic Cancer Group. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial. Trials 2021;22:313. [PMID: 33926539 DOI: 10.1186/s13063-021-05248-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Garnier J, Ewald J, Marchese U, Gilabert M, Moureau-Zabotto L, Giovannini M, Poizat F, Delpero JR, Turrini O. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. Eur J Surg Oncol 2020;46:1510-5. [PMID: 32146053 DOI: 10.1016/j.ejso.2020.02.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Andersson R, Haglund C, Seppänen H, Ansari D. Pancreatic cancer - the past, the present, and the future. Scand J Gastroenterol 2022;:1-9. [PMID: 35477331 DOI: 10.1080/00365521.2022.2067786] [Reference Citation Analysis]
38 Auclin E, Marthey L, Abdallah R, Mas L, Francois E, Saint A, Cunha AS, Vienot A, Lecomte T, Hautefeuille V, de La Fouchardière C, Sarabi M, Ksontini F, Forestier J, Coriat R, Fabiano E, Leroy F, Williet N, Bachet JB, Tougeron D, Taieb J. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Br J Cancer 2021;124:1941-8. [PMID: 33772154 DOI: 10.1038/s41416-021-01341-w] [Reference Citation Analysis]
39 Brada LJH, Walma MS, Daamen LA, van Roessel S, van Dam RM, de Hingh IH, Liem MLS, de Meijer VE, Patijn GA, Festen S, Stommel MWJ, Bosscha K, Polée MB, Yung Nio C, Wessels FJ, de Vries JJJ, van Lienden KP, Bruijnen RC, Los M, Mohammad NH, Wilmink HW, Busch OR, Besselink MG, Quintus Molenaar I, van Santvoort HC; Dutch Pancreatic Cancer Group. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms. J Surg Oncol 2021;124:589-97. [PMID: 34115379 DOI: 10.1002/jso.26567] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Schmocker RK, Delitto D, Wright MJ, Ding D, Cameron JL, Lafaro KJ, Burns WR, Wolfgang CL, Burkhart RA, He J. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. J Am Coll Surg 2021;232:405-13. [PMID: 33338577 DOI: 10.1016/j.jamcollsurg.2020.11.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
41 Tchelebi LT, Lehrer EJ, Trifiletti DM, Sharma NK, Gusani NJ, Crane CH, Zaorsky NG. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis. Cancer 2020;126:2120-31. [PMID: 32125712 DOI: 10.1002/cncr.32756] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
42 Casolino R, Braconi C, Malleo G, Paiella S, Bassi C, Milella M, Dreyer SB, Froeling FEM, Chang DK, Biankin AV, Golan T. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Ann Oncol 2021;32:183-96. [PMID: 33248227 DOI: 10.1016/j.annonc.2020.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]